Abstract
The present invention is related to the manufacturing of mRNA for use in immunotherapy or for use in immunotherapy screening or monitoring. Compared to existing methods the present approach is plasmid-free, fast and inexpensive, allowing screening of potential neoantigen in immunotherapy.
| Original language | English |
|---|---|
| Patent number | WO2021185833A1 |
| IPC | A61K39/00,C12N15/10; |
| Publication status | Published - 23 Sept 2021 |